DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The "China Cancer Drugs Market, by Drugs, Cancer, Therapy, and Companies" report has been added to ResearchAndMarkets.com's offering.

Anti-Cancer drugs are the drugs which are used to reduce or prevent the cell proliferation of cancerous tissues. China Cancer Drugs Market is projected to reach US$ 30 Billion by the year 2024; owing to the increasing prevalence of various types of cancer, changing lifestyle & dietary habits, growing aging population, rising demand of targeted drug therapy and the patent expiration of key cancer drugs. Cancer is one of the leading causes of death worldwide and is a major public health burden in both developed and developing countries.

The rate of cancer incidences in China is exploding very rapidly; nearly 4 million people diagnosed and almost 3 million died from it. For instance, due to increasing air pollution over the last couple of years, lung cancer has increased 50% in Beijing only. Anticancer drugs act like an inhibitor that prevents cancer cells to grow.

In addition, factors like growing awareness regarding cancer diagnosis & treatment, advancement in cancer drugs and therapies, rise in cancer awareness programs like breast cancer screening, investment in healthcare infrastructure are expected to drive China anti-cancer drugs market positively over the forecast period. However, major side-effects of cancer drugs and its high cost are certainly restraining the China anti-cancer drugs market to reach its full potential.

This market research report provides a complete analysis of the China Cancer Drugs Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Drugs

Cytotoxic Drugs Antimetabolities Plant Alkaloids Alkylating Agents Targeted Drugs Monoclonal Antibiotics Hormonal Drugs Traditional Chinese Medicine (TCM) Others

By Cancer

Lung Cancer Stomach Cancer Breast Cancer Esophageal Cancer Liver Cancer Others

By Therapy

Chemotherapy Targeted Therapy Hormonal Therapy Others

Companies Covered in the Report

Merck Celegene Eli Lilly Roche Sino BioPharma

For more information about this report visit https://www.researchandmarkets.com/research/v5sc4x/china_30_bn?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005448/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/23/2018 09:28 AM/DISC: 08/23/2018 09:28 AM

http://www.businesswire.com/news/home/20180823005448/en